June 19, 2020
NanoCarrier said on June 17 that its cancer drug NC-6004 achieve the primary endpoint in a PIIa study investigating the drug in combination with the anti-PD-1 antibody Keytruda (pembrolizumab) for the treatment of head and neck cancer. The study was...read more